Alonzo Ross

Dr. Alonzo Ross


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2013 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YRYulian P. Ramirez
Yulian P. Ramirez
JWJessica L. Weatherbee
Jessica L. Weatherbee
RWRichard Wheelhouse
Richard Wheelhouse
ARAlonzo Ross
Alonzo Ross
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12–14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy.

16 September 2009 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
CGCandace A. Gilbert
Candace A. Gilbert
ARAlonzo Ross
Alonzo Ross

31 August 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CGCandace A. Gilbert
Candace A. Gilbert
MDMarie-Claire Daou
Marie-Claire Daou
RMRichard P. Moser
Richard P. Moser
ARAlonzo Ross
Alonzo Ross
Malignant gliomas are treated with a combination of surgery, radiation, and temozolomide (TMZ), but these therapies ultimately fail due to tumor recurrence. In glioma cultures, TMZ treatment significantly decreases neurosphere formation; however, a small percentage of cells survive and repopulate the culture. A promising target for glioma therapy is the Notch signaling pathway. Notch activity is upregulated in many gliomas and can be suppressed using γ-secretase inhibitors (GSI). Using a neurosphere recovery assay and xenograft experiments, we analyzed if the addition of GSIs with TMZ treatment could inhibit repopulation and tumor recurrence. We show that TMZ + GSI treatment decreased neurosphere formation and inhibited neurosphere recovery. This enhancement of TMZ treatment occurred through inhibition of the Notch pathway and depended on the sequence of drug administration. In addition, ex vivo TMZ + GSI treatment of glioma xenografts in immunocompromised mice extended tumor latency and survival, and in vivo TMZ + GSI treatment blocked tumor progression in 50% of mice with preexisting tumors. These data show the importance of the Notch pathway in chemoprotection and repopulation of TMZ-treated gliomas. The addition of GSIs to current treatments is a promising approach to decrease brain tumor recurrence. Cancer Res; 70(17); 6870–9. ©2010 AACR.

8 August 2005 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
FLFenghua Liu
Fenghua Liu
SWStefan Wagner
Stefan Wagner
RCRobert B. Campbell
Robert B. Campbell
JNJeffrey A. Nickerson
Jeffrey A. Nickerson
CSCelia A. Schiffer
Celia A. Schiffer
ARAlonzo Ross
Alonzo Ross

30 October 2007 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
LLLi Li
Li Li
ARAlonzo Ross
Alonzo Ross

31 October 2002 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
LLLi Li
Li Li
FLFenghua Liu
Fenghua Liu
ARAlonzo Ross
Alonzo Ross